These 2 ‘Strong Buy’ Penny Stocks Could Surge Over 200%, Say Analysts

Risk and reward are the watchwords of all investing, and that’s especially true in the stock markets. Business cycles turn up and down, economies rise and fall, companies succeed or fail on idiosyncratic grounds – it takes a special kind of risk tolerance to try and read the tea leaves scattered on Wall Street.

But the savvy investor knows that tolerating risk is the key to success – and that few stock segments offer a better reward potential, for the risk involved, than the penny stocks. These shares, priced under $5 each, can offer an attractive combination of low cost of entry and solid potential for high-percentage returns, and triple-digit share appreciation is not uncommon. The risk – if these shares turn south, the losses can be just as heavy.

Still, for the risk-friendly investors, the ‘pennies’ are a popular choice, and that brings these low-cost shares onto the analysts’ radar screens. In fact, two in particular have caught the experts’ eyes – for their potential to surge over 200%. Furthermore, according to the TipRanks database, each has earned a “Strong Buy” consensus rating from the analyst community.

Clearside Biomedical (CLSD)

We’ll start with Clearside Biomedical, a medical research firm focused on ocular health. Specifically, Clearside is working on the development of new treatments for serious diseases that affect the back of the eye. The company describes its goal as restoring and preserving vision, and has developed a patented suprachoroidal space (SCS) microinjector, a novel delivery mechanism that can direct the therapeutic agent directly to the back of the eye.

Clearside currently has one product, Xipere, approved for use in the US. This is the firm’s first commercial product, and the first approved therapeutic agent designed specifically for SCS delivery. The drug is a treatment for macular edema associated with uveitis, the first such therapy on the market, and has been licensed to Bausch + Lomb for commercialization in the US and Canada.

Story continues

In addition, the company is working on a pipeline of…


Read More

Recommended For You

Leave a Reply

Your email address will not be published. Required fields are marked *

Discover more from Investor News Blog Finance Exchange News

Subscribe now to keep reading and get access to the full archive.

Continue reading